about
Recent advances in understanding myelofibrosis and essential thrombocythemiaProperties and biological roles of TET proteins during embryogenesis and in hematopoiesisTET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesisHeterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patientsThrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint.p53 at the crossroads of MPN treatment.p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging.An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia.Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in gliomaMyeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.Ph(-) myeloproliferative neoplasm red blood cells display deregulation of IQGAP1-Rho GTPase signaling depending on CALR/JAK2 status.TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.DNA binding of the p21 repressor ZBTB2 is inhibited by cytosine hydroxymethylation.CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress.JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect.CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent mannerGenetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.Eltrombopag, a potent stimulator of megakaryopoiesis.Identification of MPL R102P Mutation in Hereditary Thrombocytosis.Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies.AKT1 represses gene conversion induced by different genotoxic stresses and induces supernumerary centrosomes and aneuploidy in hamster ovary cells.Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals.Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone.Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.
P50
Q26748543-BF3FF842-A4BF-45D7-BC8F-50D3FC77F757Q28085708-BDEFB3F2-D38F-428E-88DD-53892D584AE1Q28507642-BFB7CF60-4C0C-44D4-84CB-B0FC58653673Q28533511-F4705996-CEE2-429E-8A2A-CD9101587372Q33409340-EA35A88B-D2EF-4B0F-99C8-DDB84DA8CF88Q33419236-0F43C9AD-FB97-45AB-A84A-760535577A24Q33430602-408ABF9B-290E-4C6C-AF87-60D7B4FE3B38Q33437766-4DB1D183-3740-4020-8095-66175CC0F41BQ33822067-92408487-3240-4489-8F44-1C826C6A0EE1Q33987032-5CE18B25-EA9E-406B-AB56-48DF017F9484Q34684316-C43767BC-B72B-4BF7-9019-2063FD7790FBQ37292779-9ACC553C-65E1-4C94-9CF1-5A92FD304A9BQ37602911-F7635780-C0D9-4A6E-BF24-07BA2950BFE1Q37697462-B4B112FC-A43C-4608-A3BF-AE0DA3FC7A10Q38285258-6603BAD7-C4C8-4ED5-94E3-0D94496224A5Q38625843-BA875A69-AFF2-4114-8CA9-7874C39A1ABBQ38723774-B480AEAA-D971-456F-A5A8-43D60223F0CAQ38749787-7B790843-9FF8-4F98-88A2-D115F9960981Q38764952-AEF69AB1-C481-4A6C-A38F-8B909D45578AQ38811734-B3C25FF6-7DFB-4356-B468-BA5DAEFD0ECDQ38816577-C9343258-F084-4D06-A1F5-8C4384575FCFQ38829270-B667321D-8804-46E2-AB66-88AC554D3B64Q39005258-47F8AC59-67B9-411F-B7BA-FB6B0E8D88D6Q39017410-8900886D-4079-4895-B3E9-465595B4ABEFQ39154440-0CAF9FAA-EBA6-40BF-9FA9-BF657C8F8A80Q39976590-FC0839F1-A827-49F5-97F6-D1D793989F77Q40714444-3BEEDF6F-09D1-4D45-B9FB-7A980C585EBAQ41553248-0F7BFC1F-F04A-44ED-BE5F-EB3631E29849Q41684028-3295F9A6-447A-40A0-82F1-B551C8B2B21CQ42293267-A48789AB-67FC-4479-995B-40885F9DF3A7Q42335815-D9E6F750-E680-41DF-9334-4037156EDF3DQ42363263-E063FCC1-6C8B-4D23-BFD5-D730E1054873Q42520569-0C426FA8-5653-4CCE-A434-1EA5413C4261Q42729833-24E19E40-8993-4B3A-8CC6-1CD9D7B23E98Q43808876-61B5CD76-3DD8-4472-B7A3-F88D72DFFA5BQ45078007-BB216323-FEA1-4B8F-873E-BE2B8260D9AEQ46325069-6A4565FF-E2B6-4546-9599-A30E218D5AB4Q46350105-1E9F6766-18FE-4876-B5AE-19764B919F9DQ46900710-18664F36-1DDE-4F3A-B45D-3CB83D81A0ADQ47363826-C6A4D6E6-C5F5-483D-BFEE-F95CF8A28208
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Isabelle Plo
@ast
Isabelle Plo
@en
Isabelle Plo
@es
Isabelle Plo
@nl
Isabelle Plo
@sl
type
label
Isabelle Plo
@ast
Isabelle Plo
@en
Isabelle Plo
@es
Isabelle Plo
@nl
Isabelle Plo
@sl
prefLabel
Isabelle Plo
@ast
Isabelle Plo
@en
Isabelle Plo
@es
Isabelle Plo
@nl
Isabelle Plo
@sl
P106
P21
P31
P496
0000-0002-5915-6910